Imidazoline Antihypertensive Drugs: Selective I 1-Imidazoline Receptors Activation

Cardiovascular Therapeutics

Volumn 30, Issue 4, 2012, Pages 209-216

  Nikolic, K ^a   Agbaba, D ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

2 Adrenergic receptors; Centrally acting antihypertensives; Clonidine; Hypertension; Imidazoline receptors; Rilmenidine

Indexed keywords

4 CHLORO 2 (2 IMIDAZOLIN 2 YLAMINO)ISOINDOLINE; 4 IODOCLONIDINE; AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; APRACLONIDINE; CLONIDINE; EFAROXAN; IDAZOXAN; IMIDAZOLE 4 ACETIC ACID RIBOTIDE; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I2 RECEPTOR; LNP 911; LOFEXIDINE; METIZOLINE; MOXONIDINE; RILMENIDINE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CARDIOVASCULAR FUNCTION; DRUG BINDING; HUMAN; HYPERTENSION; HYPOTENSION; INTRAOCULAR PRESSURE; LIVER MEMBRANE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SODIUM URINE LEVEL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; IMIDAZOLINE RECEPTORS; IMIDAZOLINES; LIGANDS; TREATMENT OUTCOME;

EID: 84863219482     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00269.x     Document Type: Review

References (97)

1. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: Differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984;230:232-236.
2. Tibirica E, Feldman J, Bousquet P. Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anesthetized rats. J Pharmacol Exp Ther 1988;244:1062-1066.
3. Ernsberger P, Guiliano R, Willette RN, Reis DJ. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990;253:408-418.
4. Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands. Ann Rev Pharmacol Toxicol 1996;36:511-544.
5. Ernsberger P, Haxhiu MA. The I1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla. Am J Physiol 1997;273:R1572-R1579.
6. Anastassiadou M, Danoun S, Crane L, et al.Synthesis and pharmacological evaluation of imidazoline sites I1 and I2 selective ligands. Bioorg Med Chem 2001;9:585-592.
7. Chan CKS, Burke SL, Head GA. Contribution of imidazoline receptors and α2-adrenoceptors in the rostral ventrolateral medulla to sympathetic baroreflex inhibition by systemic rilmenidine. J Hypertension 2007;25:147-155.
8. Knaus A, Zong X, Beetz N, Jahns R, Lohse MJ, Biel M, Hein L. Direct inhibition of cardiac HCN pacemaker channels by clonidine. Circulation 2007;115:872-880.
9. Head GA, Chan CKS, Burke SL. Relationship between imidazoline and α2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents. J Auton Nerv Syst 1998;72:163-169.
10. Piletz JE, Ivanov TR, Sharp JD, et al. Imidazoline receptor antisera-selected (IRAS) cDNA: Cloning and characterization. DNA Cell Biol 2000;19:319-329.
11. Zhang J, Abdel-Rahman AA. Inhibition of nischarin expression attenuates rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 1/2 production in the rostral ventrolateral medulla of rats. J Pharmacol Exp Ther 2008;324:72-78.
12. Lim KP, Hong W. Human nischarin/imidazoline receptor antisera-selected protein is targeted to the endosomes by a combined action of a PX domain and a coiled-coil region. J Biol Chem 2004;279:54770-54782.
13. Alahari SK, Nasrallah H. A membrane proximal region of the integrin α5 subunit is important for its interaction with nischarin. Biochem J 2004;377:449-457.
14. Heemskerk FMJ, Dontenwill M, Greney H, Vonthron C, Bousquet P. Evidence for the existence of imidazoline-specific binding sites in synaptosomal plasma membranes of the bovine brainstem. J Neurochem 1998;71:2193-2202.
15. Piletz JE, Sletten K. Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther 1993;267:1493-1502.
16. 1 imidazoline receptors. Definition, characterisation, distribution and transmembrane signaling. Ann N Y Acad Sci 1995;763:22-42.
17. 1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol Pharmacol 1996;49:668-675.
18. 1 imidazoline receptors to the cAMP pathway: Studies with a highly selective ligand, benazoline. Mol Pharm 2000;57:1142-1151.
19. 125I] Para-iodoclonidine reveals a new subtype of imidazoline specific sites in synaptosomal plasma membranes of the bovine brainstem. J Neurochem 1998;71:2193-2202.
20. Meeley MP, Ernsberger PR, Granata AR, Reis DJ. An endogenous clonidine-displacing substance from bovine brain: Receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci 1986;38:1119-1126.
21. Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P. Evidence for the existence of a homogenous population of imidazoline receptors in the human brainstem. Eur J Pharmacol 1988;150:401-402.
22. Holt A, Wieland B, Baker GB. Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands. Br J Pharmacol 2004;143:495-507.
23. Limon I, Coupry I, Lanier SM, Parini A: Purification and characterization of mitochondrial imidazoline-guanidinium receptive site from rabbit kidney. J Biol Chem 1992;267:21645-21649.
24. Wang H, Regunathan S, Meeley MP, Reis DJ. Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells. Mol Pharmacol 1992;42:792-801.
25. 2-adrenoceptor and non adrenergic idazoxan binding sites. J Pharm Exp Ther 1991;260:417-426.
26. Tesson F, Parini A. Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex. Eur J Pharmacol 1991;208:81-83.
27. Tesson F, Limon I, Parini A. Tissue-specific localization of mitochondrial imidazoline-guanidinium receptive sites. Eur J Pharmacol 1992;219:335-338.
28. 2-imidazoline receptors in human glioblastomas. Neuroreport 1996;7:1393-1396.
29. Coupry I, Limon I, Tesson F, Lachaud V, Gargalidismoudanos C, Parini A.The imidazoline-guanidinium receptive site: A subtype of imidazoline receptors. Therapie 1992;47:519-524.
30. 2-sites. Br J Pharmacol 1994;112:1065-1070.
31. Gothert M, Bruess M, Boenisch H, Molderings GJ. Presynaptic imidazoline receptors: New developments in characterization and classification. Ann N Y Acad Sci 1999;881:171-184.
32. Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA. Imidazolines and pancreatic hormone secretion. Ann NY Acad Sci 1999;881:217-228.
33. 3 imidazoline receptor antagonist KU14R and related 2, 3-dihydrobenzo[b]furan derivatives. Synthesis 2001;10:1546-1550.
34. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP. 'Seeing through a glass darkly': Casting light on imidazoline 'I' sites. Trends Pharmacol Sci 1998;19:381-390.
35. Efendic S, Efanov AM, Berggren PO, Zaitsev SV. Two generations of insulinotropic imidazoline compounds. Diabetes 2002;5(Suppl. 3):S448-S454.
36. Atlas D, Burstein Y. Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS Lett 1984;170:387-390.
37. Hensley ML, Meeley MP, McCauley PM, Ernsberger P, Reis DJ. Clonidine-displacing substance is present in peripheral tissues of the rat. Am J Hypertens 1989;2:917-919.
38. Meeley MP, Hensley ML, Ernsberger P, Felsen D, Ernsberger DJ. Evidence for a bioactive clonidine-displacing substance in peripheral tissues and serum. Biochem Pharmac 1992;44:733-740.
39. Atlas D.Molecular and physiological properties of clonidine-displacing substance. Ann N Y Acad Sci 1995;763:314-324.
40. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ.Agmatine: An endogenous clonidine-displacing substance in the brain. Science 1994;263:966-969.
41. Prell GD, Martinelli GP, Holstein GR, et al. Imidazoleacetic acid-ribotide: An endogenous ligand that stimulates imidazol(in)e receptors. Proceedings of the National Academy of Sciences of the United States of America, 2004;101:13677-13682.
42. Halaris A, Plietz J. Agmatine: Metabolic pathway and spectrum of activity in brain. CNS Drugs 2007;21:885-900.
43. 1-imidazoline receptor, mediates inhibitory effect of agmatine on cellular morphine dependence. Biochem Pharmacol 2005;70:1079-1087.
44. Halaris A, Piletz JE. Relevance of imidazoline receptors and agmatine to psychiatry. A decade of progress. Ann N Y Acad Sci 2003;1009:1-20.
45. 2A receptors in adrenal gland of rats. Neurosci Lett 2010;468:297-299.
46. Husbands SM, Glennon RA, Gorgerat S, et al. Beta-carboline binding to imidazoline receptors. Drug Alcohol Depend 2001;64:203-208.
47. 1-imidazoline receptors. Br J Pharmacol 2000;129:1057-1059.
48. Parker ChA, Anderson NJ, Robinson ESJ, et al. Harmane and harmalan are bioactive components of classical clonidine-displacing substance. Biochemistry 2004;43:16385-16392.
49. Parker CA, Hudson AL, Nutt DJ, et al. Extraction of active clonidine-displacing substance from bovine lung and comparison with clonidine-displacing substance extracted from other tissues. Eur J Pharmacol 1999;378:213-221.
50. 2 receptors. Eur J Pharmacol 1998;353:123-135.
51. 1-imidazoline sites in bovine adrenal medullary membranes. Naunyn Schmiedeberg's Arch Pharmacol 1993;348:70-76.
52. 2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes. Biochem Pharmacol 1991;42:569-584.
53. Felsen D, Ernsberger P, Sutaria PM, et al. Identification, localization and functional analysis of imidazoline and alpha adrenergic receptors in canine prostate. J Pharmacol Exp Ther 1994;268:1063-1071.
54. 1 imidazoline binding sites. Neurochem Int 1997;30:17-23.
55. 1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res 1997;749:335-339.
56. 1 receptors. Exp Eye Res 2001;72:331-339.
57. Smyth DD, Penner SB. Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Ann N Y Acad Sci 1999;881:344-357.
58. Nguyen TT, De Lean A. Nonadrenergic modulation by clonidine of the cosecretion of catecholamines and enkephalins in adrenal chromaffin cells. Can J Physiol Pharmacol 1987;65:823-827.
59. 2-adrenoceptors in the central hypotensive effects of imidazoline-like drugs. Ann N Y Acad Sci 1999;881:272-278.
60. 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur J Pharmacol 1995;282:19-28.
61. Feldman J, Tibiric E, Bricca G, Dontenwill M, Belcourt A, Bousquet P. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br J Pharmacol 1990;100:600-604.
62. 2-adrenergic and nonadrenergic mechanisms in central blood pressure regulation. Circulation 2002;105:1116-1121.
63. 1 imidazoline receptors. Mol Pharmacol 2002;62:181-191.
64. Treder AP, Andruszkiewicz R, Zgoda W, Ford C, Hudson AL. New analogues of agmatine with higher affinity to imidazoline receptors. Bioorg Med Chem Lett 2009;19:1009-1011.
65. 2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues. J Med Chem 2003;46:2169-2176.
66. Ruffolo RR, Bondinell W, Hieble JP. Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem 1995;38:3681-3716.
67. 1 imidazoline receptor selective ligand with hypotensive activity. J Med Chem 2001;44:1588-1593.
68. 1 imidazoline receptors. Br J Pharmacol 2004;142:609-617.
69. Bruban V, Feldman J, Greney H, et al. Respective contributions of α-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs. Br J Pharmacol 2001;133:261-266.
70. Nikolic K, Filipic S, Agbaba D. QSAR study of imidazoline antihypertensive drugs. Bioorg Med Chem 2008;16:7134-7140.
71. 1-imidazoline receptor ligands. SAR & QSAR Environ Res 2008;20:133-144.
72. Filipic S, Nikolic K, Krizman M, Agbaba D. The quantitative structure: Retention relationship (QSRR) analysis of some centrally acting antihypertensives and diuretics. QSAR Comb Sci 2008;27:1036-1044.
73. Eric S, Pavlovicc M, Popovic ; G, Agbaba D. Study of retention parameters obtained in RP-TLC system and their application on QSAR/QSPR of some alpha adrenergic and imidazoline receptor ligands. J Chromatogr Sci 2007;45:140-145.
74. Eric S, Solmajer T, Zupan J, Novic M, Oblak M, Agbaba D. Prediction of selectivity of α1-adrenergic antagonists by counterpropagation neural network (CP-ANN). Farmaco 2004;59:389-395.
75. Eric S, Solmajer T, Zupan J, Novic M, Oblak M, Agbaba D. Quantitative structure-activity relationships of α1 adrenergic antagonists. J Mol Model 2004;10:139-150.
76. Carrieri A, Brasili L, Leonetti F, Pigini M, Giannella M, Bousquet P, Carotti A. 2-D and 3-D modeling of imidazoline receptor ligands: Insights into pharmacophore. Bioorg Med Chem 1997;5:843-856.
77. Pigini M, Bousquet P, Carotti A, et al. Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity. Bioorg Med Chem 1997;5:833-841.
78. 1-receptor ligand 2-(2-biphenyl-2-yl-1-methyl-ethyl)-4, 5-dihydro-1H-imidazole. Lett Drug Des Discov 2005;2:571-578.
79. Pigini M, Bousquet P, Brasili L, et al. Binding of tracizolines to the imidazoline receptor. Role of lipophilicity in quantitative structure-activity relationship models. Ann N Y Acad Sci 1999;881:118-122.
80. 1 imidazoline binding site ligands. Med Chem Res 2004;13:170-189.
81. 2-imidazoline binding sites nature and functions. J Med Chem 2008;51:5130-5134.
82. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-2610.
83. Genissel P, Bromet N, Fourtillan JB, Mignot A, Albin H. Pharmacokinetics of rilmenidine. Am J Cardiol 1988;61:47D-53D.
84. Valet P, Tran MA, Damase-Michel C, et al. Rilmenidine (S 3341) and the sympatho-adrenal system: Adrenoreceptors, plasma and adrenal catecholamines in dogs. J Auton Pharmacol 1988;8:319-326.
85. Trenk D, Wagner F, Jahnchen E, Planitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol 1987;27:988-993.
86. Kirch W, Hutt HJ, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990;30:1088-1095.
87. Mitrovic V, Patyna W, Huting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991;5:967-972.
88. Trimarco B, Rosiello G, Sarno D, Lorino G, Rubattu S, Deluca N, Volpe M. Effects of one-year treatment with rilmenidine on systemic hypertension- induced left ventricular hypertrophy in hypertensive patients. Am J Cardiol 1994;74:36A-42A.
89. Ollivier JP, Christen MO. I1-imidazoline-receptor agonists in the treatment of hypertension: An appraisal of clinical experience. J Cardiovasc Pharmacol 1994;24:S39-S48.
90. Sadowski Z. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: A double-blind, randomized, controlled (versus nifedipine) study. J Hypertens Suppl 1998;16:S55-S62.
91. Koldas L, Ayan F, Ikitimur B. Short term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: Comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. Jpn Heart J 2003;44:693-704.
92. Kline RL, Cechetto DF. Renal effects of rilmenidine in anaesthetized rats: importance of renal nerves. J Pharmacol Exp Ther 1993;266:1556-1562.
93. Chan SLF, Brown CA, Scarpello KE, Morgan NG. The imidazoline site involved in control of insulin secretion: Characteristics that distinguish it from I1 and I2 sites. Br J Pharmacol 1994;112:1065-1070.
94. + channels in mouse pancreatic β-cells. Br J Pharmacol 1990;101:115-120.
95. + ATP channels in insulinsecreting cells. Eur J Pharmacol 1991;204:41-48.
96. 2 sites. Ann N Y Acad Sci 1995;763:153-156.
97. Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: A review of its use in essential hypertension. Drugs 2006;66:477-496.